|01/12/15||MannKind CEO Alfred Mann to Transition to Executive Chairman; COO and President Hakan Edstrom Appointed to CEO|
|Alfred Mann to Remain Focused on Development and Financing of Future Products of MannKind
VALENCIA, Calif., Jan. 12, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), a biopharmaceutical-based technology company, today announced that Alfred Mann, the company's founder, retired from his role as Chief Executive Officer effective January 9, 2015 and will transition to Executive Chairman. Mr. Mann intends to remain engaged with the company in business matters, including those relating to... |
|01/08/15||MannKind Earns $50 Million in Milestone Payments From Sanofi|
|VALENCIA, Calif., Jan. 8, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced that it has earned a total of $50 million in milestone payments in connection with the satisfaction of manufacturing milestones specified in its collaboration and licensing agreement with Sanofi. Pursuant to the agreement, MannKind previously received a $150 million upfront payment and is eligible to earn up to $725 million in further development, regulatory and sales milestones, and is also eli... |
|01/07/15||MannKind Corporation to Present at the J.P. Morgan 2015 Healthcare Conference|
|VALENCIA, Calif., Jan. 7, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), focused on discovering, developing and commercializing therapeutic products for diabetes, announced today that it will present at the 33RD Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2015 at 1:30 PM (PST) at Westin St. Francis Hotel in San Francisco, California.
Interested parties can access a link to the live webcast of the presentations from the News & Events section of the Com... |